Pasithea Therapeutics (KTTA) Capital Expenditures (2021 - 2023)
Pasithea Therapeutics recorded quarterly Capital Expenditures of -$36.0 in Q4 2023, up 99.84% quarter-over-quarter from -$22659.0 in Q3 2023, and down 100.04% year-over-year from $92725.0 in Q4 2022.
Pasithea Therapeutics' Capital Expenditures history runs 3 years deep, the most recent figure standing at -$36.0 for Q4 2023.
- In Q4 2023, Capital Expenditures fell 100.04% year-over-year to -$36.0; the TTM figure through Dec 2023 stood at $34301.0 (down 67.97% YoY), while the FY2023 annual figure was $34301.0, down 67.97% from the prior year.
- Capital Expenditures came in at -$36.0 for Q4 2023 at Pasithea Therapeutics, up from -$22659.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $92725.0 in Q4 2022 to a low of -$22659.0 in Q3 2023.
- A 3-year average of $17148.3 and a median of $5486.0 in 2022 frame the typical range for Capital Expenditures.
- On a YoY basis, Capital Expenditures climbed as much as 2662.07% in 2023 and fell as far as 513.03% in 2023.
- Pasithea Therapeutics' Capital Expenditures stood at $12933.0 in 2021, then soared by 616.96% to $92725.0 in 2022, then slumped by 100.04% to -$36.0 in 2023.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$36.0, -$22659.0, and $3108.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -36.00 |
| Dec 31, 2023 | -36.00 |
| Sep 30, 2023 | -22,659.00 |
| Sep 30, 2023 | -22,659.00 |
| Jun 30, 2023 | 3,108.00 |
| Jun 30, 2023 | 3,108.00 |
| Mar 31, 2023 | 53,888.00 |
| Mar 31, 2023 | 53,888.00 |
| Dec 31, 2022 | 92,725.00 |
| Dec 31, 2022 | 92,725.00 |
| Sep 30, 2022 | 5,486.00 |
| Sep 30, 2022 | 5,486.00 |
| Jun 30, 2022 | 6,939.00 |
| Jun 30, 2022 | 6,939.00 |
| Mar 31, 2022 | 1,951.00 |
| Mar 31, 2022 | 1,951.00 |
| Dec 31, 2021 | 12,933.00 |
| Dec 31, 2021 | 12,933.00 |